*** CHEMICAL IDENTIFICATION ***
RTECS NUMBER : NM9690000
CHEMICAL NAME : Interferon-alpha-2 (human leucocyte protein moiety
reduced)
CAS REGISTRY NUMBER : 75432-97-2
LAST UPDATED : 199806
DATA ITEMS CITED : 7
COMPOUND DESCRIPTOR : Drug
Human
SYNONYMS/TRADE NAMES :
* alpha-2 Interferon
*** HEALTH HAZARD DATA ***
** ACUTE TOXICITY DATA **
TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Subcutaneous
SPECIES OBSERVED : Human - man
DOSE/DURATION : 552000 units/kg/2W-I
TOXIC EFFECTS :
Sense Organs and Special Senses (Eye) - effect, not otherwise specified
REFERENCE :
AJMEAZ American Journal of Medicine. (Technical Pub., 875 Third Ave., New
York, NY 10022) V.1- 1946- Volume(issue)/page/year: 82,181,1987
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Intravenous
SPECIES OBSERVED : Rodent - rat
DOSE/DURATION : >165000 ku/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo,
Japan) Volume(issue)/page/year: -,181,1995
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Intramuscular
SPECIES OBSERVED : Rodent - rat
DOSE/DURATION : >330000 ku/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo,
Japan) Volume(issue)/page/year: -,181,1995
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Intravenous
SPECIES OBSERVED : Rodent - mouse
DOSE/DURATION : >165000 ku/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo,
Japan) Volume(issue)/page/year: -,181,1995
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Intramuscular
SPECIES OBSERVED : Rodent - mouse
DOSE/DURATION : >330000 ku/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo,
Japan) Volume(issue)/page/year: -,181,1995
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Intravenous
SPECIES OBSERVED : Primate - monkey
DOSE/DURATION : >260000 ku/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo,
Japan) Volume(issue)/page/year: -,181,1995
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Intramuscular
SPECIES OBSERVED : Primate - monkey
DOSE/DURATION : >260000 ku/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo,
Japan) Volume(issue)/page/year: -,181,1995
*** END OF RECORD ***
|
|
|
ALL Chemical Property And Toxicity Analysis PAGES IN THIS GROUP
| NAME | CAS |
D-myo-Inositol,O-2,6-diamino-2,6-dideoxy-alpha-D-glucopyranosyl-(1-4)-O-(O-2,6-diamino-2, 6-dideoxy-beta-L-idopyranosyl-(1-3)-beta-D-ribofuranosyl-(1-5))-3-amino-2,3- dideoxy-
| 91421-97-5 |
D-myo-Inositol,O-2,3-diamino-dideoxy-alpha-D-gucopyranosyl-(1-1)-O-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-D-erythro-hexopyranosyl(1-3)-2,4-diamino-6-((4-amino-2-hy droxy-1-oxobutyl)amino)-2,4,5,6-tetradeoxy-, (S)-
| 161822-04-4 |
D-myo-Inositol,O-2,6-diamino-2,6-dideoxy-alpha-D-glucopyranosyl-(1-4)-O-(beta-D-ribofuranosyl-(1-5))-1,3-diamino-1,3-dideoxy-
| 52248-05-2 |
epi-Inositol,2,3-dideoxy-2-((2-hydroxy-1-(hydroxymethyl)ethyl)amino)-4-C-(hydroxymethyl )-
| 112653-29-9 |
D-chiro-Inositol,1,5-dideoxy-5-(hydroxymethyl)-1-((4,5,6-trihydroxy-3-(hydroxymethyl)-2- cyclohexen-1-yl)amino)-,(1S-(1-alpha,4-alpha,5-beta,6-alpha))-
| 39318-73-5 |
2-Indolinone,3-(3-dimethylaminopropyl)-1-methyl-3-phenyl-,hydrochloride
| 10565-90-9 |
D-chiro-Inositol,O-alpha-D-glucopyranosyl-(1-4)-O-beta-D-glucopyranosyl-(1-3)-1,5,6-trideoxy-5-(hydroxymethyl)-1-((4,5,6-trihydroxy-3-(hydroxymethyl)-2-cycloh exen-1-yl)amino)-,(1S-(1-alpha,4-alpha,5-beta,6-alpha))-
| 12650-71-4 |
Inositol,hexakis(2-(p-chlorophenoxy)-2-methylpropionate), myo-
| 14496-74-3 |
Inositol, hexakis(dihydrogen phosphate), myo-
| 83-86-3 |
Inositol, hexakis(dihydrogen phosphate), calciummagnesium salt, myo-
| 3615-82-5 |
Inositol, hexakis(dihydrogen phosphate) sodium salt,myo-
| 14306-25-3 |
Inositol, hexakis(disodium phosphate), hydrate (135)
| 14306-25-3 |
myo-Inositol, hexakis(5-fluoro-3-pyridinecarboxylate)
| 23763-98-6 |
myo-Inositol, hexakis(hydrogen sulfate), hexasodiumsalt
| 70701-62-1 |
Inositol, hexanicotinate, myo-
| 6556-11-2 |
meso-Inositol, hexanitrate
| 6556-11-2 |
2-Indolinone, 3,3-bis(2-hydroxypropyl)-1-phenyl-
| 20870-64-8 |
2-Indolinone,3-(3-(dimethylamino)propyl)-1-(methyl-2-thenylamino)-3-phenyl-
| 33391-50-3 |
scyllo-Inositol, hexanitrate
| 33391-50-3 |
D-chiro-Inositol,5-(hydroxymethyl)-1,5,6-trideoxy-1-((4,5,6-trihydroxy-3-(hydroxymethyl)-2- cyclohexen-1-yl)amino)-,(1S-(1-alpha,4-alpha,5-beta,6-alpha))-
| 38665-10-0 |
D-chiro-Inositol,1,5,6-trideoxy-3-O-beta-D-glucopyranosyl-5-(hydroxymethyl)-1-((4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl)amino)-, (1S-(1-alpha,4-alpha,5-beta, 6-alpha))-
| 37248-47-8 |
InstanetSUBSTANCE DEFINITION :Consists of butylglycol and a small quantity of ethanolREFERENCE :HUTODJ Human Toxicology. (Macmillan Press Ltd., Houndmills, Basingstoke,Hants., RG 21 2XS, UK) V.1- 1981- Volume(issue)/page/year: 8,243,1989
| 37248-47-8 |
Insularinium, 2,2'-dimethyl-, diiodide
| 32434-10-9 |
Insulin
| 9004-10-8 |
Insulin, pyrolyzate
| 9004-10-8 |
Insulin (dog)
| 12584-58-6 |
Insulin (human), 28b-L-lysine-29b-L-proline-
| 133107-64-9 |
Insulin-like growth factor I
| 67763-96-6 |
2-Indolinone,1,5-dimethyl-3-(5-phenyl-1,3,4-oxadiazol-2-ylimino)-
| 84640-78-8 |
Insulin-like growth factor I (human)
| 68562-41-4 |
Insulin-like growth factor II
| 67763-97-7 |
Insulin protamine zinc
| 9004-17-5 |
Insulin sensitizer enhancer, S18277
| 9004-17-5 |
Insulin zinc
| 8049-62-5 |
Integerrimine
| 480-79-5 |
Interferon-alpha
| 480-79-5 |
Interferon-alpha-2 (human leucocyte clone pM21protein moiety reduced)
| 98530-12-2 |
Interferon-alpha-2 (human leucocyte protein moietyreduced)
| 75432-97-2 |
Interferon-alpha-4 (human leucocyte)
| 75432-97-2 |
2-Indolinone,3,3-diphenyl-5-methoxy-1-(piperidinomethyl)-
| 81252-99-5 |
Interferon-beta, (human)SUBSTANCE DEFINITION :A polypeptide consisting of 166 amino acidsREFERENCE :KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, KandaSuda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960-
| 81252-99-5 |
Interferon A (human myeloblastoid KG-1 protein moietyreduced)
| 76543-88-9 |
Interferon-gamma (human lymphocyte protein moietyreduced)
| 82115-62-6 |
Interferon-gamma, OH-6000
| 82115-62-6 |
Interferons
| 9008-11-1 |
Interleukin 1SUBSTANCE DEFINITION :Purified interleukin 1 derived from human monocytesREFERENCE :CNREA8 Cancer Research. (Public Ledger Building, Suit 816, 6th & ChestnutSts., Philadelphia, PA 19106) V.1- 1941- Volume(issue)/page/year:47,5612,1987
| 9008-11-1 |
Interleukin-1-alpha
| 9008-11-1 |
Interleukin-1-beta
| 9008-11-1 |
Interleukin 2 (human clone pTG853 protein moietyreduced)
| 94218-75-4 |
Interleukin 2 (human clone pTIL2-21a protein moiety)
| 94218-72-1 |
|
|